About Genomic Health - Our Commitment

Home

Logon

About Genomic Health

CEO Message

Our Commitment

The Team

Oncotype DX in Breast Cancer

Genomics in Cancer

Products and Services

Press Room

Investors

Careers at Genomic Health

Our Commitment

Genomic Health is committed to improving the quality of cancer treatment decisions through the research and development of clinically validated genomic technologies.

Our commitment as an innovator in oncology:

We will put quality of care for patients first in our priorities
We will use genomics to improve the quality of treatment decisions for patients
We will safeguard the privacy of patients’ genomic information
We will use state-of-the-art science and technology supported by rigorous clinical validation

Genomic Health is committed to compliance with applicable federal, state and local statutes and regulations that affect the operation of its business in its role as a provider of healthcare services, in order to ensure that it conducts its activities with the utmost integrity and in accordance with the law. Genomic Health's compliance program furthers this commitment with internal controls that promote adherence to applicable federal and state laws.

What's New

June 2, 2008
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores

May 31, 2008
Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies


Copyright © 2008 Genomic Health, Inc. All rights reserved.	\| Contact Us \| Site Map \| Privacy \| Terms and Conditions \|